BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Durdagi S, Avsar T, Orhan MD, Serhatli M, Balcioglu BK, Ozturk HU, Kayabolen A, Cetin Y, Aydinlik S, Bagci-Onder T, Tekin S, Demirci H, Guzel M, Akdemir A, Calis S, Oktay L, Tolu I, Butun YE, Erdemoglu E, Olkan A, Tokay N, Işık Ş, Ozcan A, Acar E, Buyukkilic S, Yumak Y. The neutralization effect of montelukaston SARS-CoV-2 is shown by multiscale in silicosimulations and combined in vitro studies. Mol Ther 2021:S1525-0016(21)00521-9. [PMID: 34678509 DOI: 10.1016/j.ymthe.2021.10.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Wang X, Shi H, Zou P. Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator. Viruses 2022;14:861. [DOI: 10.3390/v14050861] [Reference Citation Analysis]
2 Urda L, Kreuter MH, Drewe J, Boonen G, Butterweck V, Klimkait T. The Petasites hybridus CO2 Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro. Viruses 2022;14:106. [PMID: 35062310 DOI: 10.3390/v14010106] [Reference Citation Analysis]
3 May BC, Gallivan KH. Levocetirizine and montelukast in the COVID-19 treatment paradigm. Int Immunopharmacol 2021;103:108412. [PMID: 34942461 DOI: 10.1016/j.intimp.2021.108412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ridgway H, Chasapis CT, Kelaidonis K, Ligielli I, Moore GJ, Gadanec LK, Zulli A, Apostolopoulos V, Mavromoustakos T, Matsoukas JM. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. Viruses 2022;14:1029. [DOI: 10.3390/v14051029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]